# The interplay between NLRP3 inflammasome and metabolic signals in gouty arthritis

**Authors:** Dongyi Cao, Hangyi Pu, Xiaolin Yuan, Zhengyan Li, Xiaoling Yu, Xiaoke Shi

PMC · DOI: 10.3389/fimmu.2026.1761121 · Frontiers in Immunology · 2026-03-12

## TL;DR

This paper explores how the NLRP3 inflammasome and metabolic signals interact in gouty arthritis, offering new insights into managing the condition through dual-target therapies.

## Contribution

The paper introduces the concept of gout as a 'metabolic-inflammatory' disorder and proposes dual-target therapeutic strategies.

## Key findings

- MSU crystals link hyperuricemia to innate immune activation via the NLRP3 inflammasome.
- Metabolic factors act as primers and amplifiers of NLRP3 inflammasome activation.
- Combining metabolic regulation with NLRP3 inhibition offers effective therapeutic interventions.

## Abstract

The pathogenesis of gouty arthritis (GA) begins with the deposition of monosodium urate (MSU) crystals in the joints. This crystal deposition triggers a critical inflammatory response by activating the NLRP3 inflammasome, which in turn drives the maturation and release of pro-inflammatory cytokines such as IL-1β. Beyond this well-defined inflammatory axis, metabolic dysregulation is increasingly recognized as a core component of GA pathogenesis. This paper systematically reviews the crosstalk between metabolic signaling and the NLRP3 inflammasome in GA, elucidating how MSU crystals serve as a bridge between hyperuricemia (HUA) and innate immune activation. Furthermore, we elaborate the dual role of metabolic factors: acting both as “primer” and “amplifiers” of NLRP3 inflammasome activation, significantly lowering its activation threshold. This mechanistic association offers novel therapeutic insights for GA management: synergistic regulation of metabolic signaling alongside targeted inhibition of NLRP3 inflammasome activation enables more effective therapeutic interventions. Defining gout as a “metabolic-inflammatory” disorder has led to the development of novel dual-target therapeutic strategies—simultaneously alleviating inflammatory symptoms while regulating metabolic abnormalities. Such approaches hold significant promise for effectively preventing and controlling gout attacks, whilst reducing the risk of long-term complications.

## Linked entities

- **Proteins:** NLRP3 (NLR family pyrin domain containing 3), IL1B (interleukin 1 beta)
- **Chemicals:** monosodium urate (PubChem CID 23690430)
- **Diseases:** gout (MONDO:0005393)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}
- **Diseases:** metabolic-inflammatory (MESH:D024821), gout (MESH:D006073), GA (MESH:D015210), inflammatory (MESH:D007249), HUA (MESH:D033461), metabolic abnormalities (MESH:D008659)
- **Chemicals:** MSU (MESH:D014527)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017287/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13017287/full.md

## References

184 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017287/full.md

---
Source: https://tomesphere.com/paper/PMC13017287